New drug YK012 tested in early leukemia trial
NCT ID NCT06580301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 through several cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YK012 (a drug given by injection)
What this could lead to
If it works, this could point toward a treatment for B-cell acute lymphoblastic leukemia that helps control the disease.
What could go wrong
This is a very early, small trial (Phase 1/2) with only 46 people. It mainly checks safety and dosing, not whether the drug works well. Side effects are possible, and the drug may not be effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Zhongshan Hospital of Dalian University
RECRUITINGDalian, Liaoning, 116001, China
Contact
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact
-
Shengjing Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110000, China
Contact
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
The Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, 550004, China
Contact
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact
-
The Second Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, 650033, China
Contact